A

s President Trump tweets yet another promise to lower drug prices, a new analysis offers an example of what can happen when the federal government negotiates with manufacturers.

During a 12-month period ended November 2015, the Veterans Choice Program, which was created by the US Department of Veterans Affairs, paid a median price of $12,500 for a month’s supply of Harvoni, a hepatitis C drug sold by Gilead Sciences. Since most patients typically are treated for two to three months, the cost was closer to $25,000 to $37,500 per person, according to the analysis in Medical Care.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories